Orgenesis Inc
NASDAQ:ORGS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alina Holdings PLC
LSE:ALNA
|
UK |
|
Axiom Properties Ltd
ASX:AXI
|
AU |
|
N
|
NetEase Inc
HKEX:9999
|
CN |
|
Cango Inc
NYSE:CANG
|
CN |
|
T
|
Transmit Entertainment Ltd
HKEX:1326
|
HK |
|
V
|
Volkswagen AG
WSE:VOW
|
DE |
|
A
|
Amerant Bancorp Inc
NYSE:AMTB
|
US |
Orgenesis Inc
Total Current Assets
Orgenesis Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orgenesis Inc
NASDAQ:ORGS
|
Total Current Assets
$761k
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Orgenesis Inc
Glance View
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 151 full-time employees. The company went IPO on 2010-07-01. The firm is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The company has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.
See Also
What is Orgenesis Inc's Total Current Assets?
Total Current Assets
761k
USD
Based on the financial report for Dec 31, 2024, Orgenesis Inc's Total Current Assets amounts to 761k USD.
What is Orgenesis Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
-10%
Over the last year, the Total Current Assets growth was -81%. The average annual Total Current Assets growth rates for Orgenesis Inc have been -69% over the past three years , -60% over the past five years , and -10% over the past ten years .
